主页 > 医学前沿 >
【文摘发布】肝门胆管癌予新辅助治疗后行原位
Author:Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, I***ani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ.
Source:Liver Transpl. 2007 Apr 10
IF:4.225(2005)
Liver transplantation after neoadjuvant chemoradiotherapy has emerged as an effective treatment for patients with localized, node-negative, unresectable hilar cholangiocarcinoma (CCA) or CCA arising in the setting of primary sclerosing cholangitis (PSC). However, concern has arisen regarding the potential for vascular complications due to high-dose neoadjuvant therapy before transplantation. We reviewed our experience with specific aims to determine the incidences of arterial, portal, and hepatic venous complications in patients transplanted for CCA compared with patients who undergo transplantation for other indications, and to describe patient outcome as a result of these vascular complications. We reviewed data for all patients who underwent liver transplantation for CCA between January 1993 and April 2006 and compared the incidences of vascular complications to whole organ and living donor recipient control groups. Sixty-eight patients underwent neoadjuvant therapy and subsequent liver transplantation. Arterial complications arose in 21%; portal venous complications arose in 22%; and overall, 40% developed vascular complications. Late hepatic artery complications occurred more often in living donor recipients transplanted for CCA compared with the living donor control group (P = 0.047). Late portal vein complications occurred more often in both whole organ and living donor recipients transplanted for CCA compared with the control groups (P = 0.01 and P = 0.009). Hepatic venous complications were rare. Patient and graft survival were not different between CCA and control patients. Liver transplantation with neoadjuvant therapy is associated with far higher rates of late arterial and portal venous complications, but these complications do not adversely affect patient and graft survival. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title:Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma.
题目：肝门胆管癌予新辅助治疗后行原位肝移植术的血管并发症
Author:Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, I***ani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ.
作者：Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, I***ani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ.
Source:Liver Transpl. 2007 Apr 10
来源：《肝脏移植学》. 2007 Apr 10
IF:4.225(2005)
影响因子：4.225(2005)
Liver transplantation after neoadjuvant chemoradiotherapy has emerged as an effective treatment for patients with localized, node-negative, unresectable hilar cholangiocarcinoma (CCA) or CCA arising in the setting of primary sclerosing cholangitis (PSC).
新辅助放化疗之后的肝移植对患有局限性、淋巴结阴性、无法切除的肝门胆管癌（CCA）或来源于原发性硬化性胆管炎（PSC）的CCA的病人来说是一种有效的治疗手段。
However, concern has arisen regarding the potential for vascular complications due to high-dose neoadjuvant therapy before transplantation.
但是，人们担心移植前的高剂量新辅助治疗有可能引发血管并发症。
We reviewed our experience with specific aims to determine the incidences of arterial, portal, and hepatic venous complications in patients transplanted for CCA compared with patients who undergo transplantation for other indications, and to describe patient outcome as a result of these vascular complications.
我们回顾分析了我们的经验，目的是为了比较因CCA行肝移植与因其他原因行肝移植的病人的动脉、门静脉及肝静脉并发症的发生率，并描述血管并发症对病人所造成的后果。
We reviewed data for all patients who underwent liver transplantation for CCA between January 1993 and April 2006 and compared the incidences of vascular complications to whole organ and living donor recipient control groups.
我们回顾了自1993年1月至2006年4月之间因CCA行肝移植的所有病人的资料，并比较了对照组与接受活体供肝移植组及接受整肝移植组的血管并发症发生率。
Sixty-eight patients underwent neoadjuvant therapy and subsequent liver transplantation. Arterial complications arose in 21%; portal venous complications arose in 22%; and overall, 40% developed vascular complications.
共有68例病人接受了新辅助治疗并随后进行了肝移植，其中21%发生了动脉并发症；22%发生了门静脉并发症；总体血管并发症发生率为40%。
Late hepatic artery complications occurred more often in living donor recipients transplanted for CCA compared with the living donor control group (P = 0.047).
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-10 17:11
医学,生命科学网